KI-Beratung Beta
Vor Ort
Merkzettel Warenkorb
Produktbild: Clinical Applications of Noncoding Rnas in Cancer

Clinical Applications of Noncoding Rnas in Cancer

168,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

24.01.2022

Abbildungen

70 illustrations (40 in full color)

Herausgeber

Subash Gupta + weitere

Verlag

Elsevier Science & Technology

Seitenzahl

478

Maße (L/B/H)

23,4/19,1/1,8 cm

Gewicht

998 g

Sprache

Englisch

ISBN

978-0-12-824550-7

Beschreibung

Portrait

Dr. Subash Chandra Gupta is an additional professor and Head at the Department of Biochemistry, All India Institute of Medical Sciences, Guwahati, India. He is currently on lien from Banaras Hindu University, Varanasi, India. Dr. Gupta did his postdoctoral training from the Ohio State University and the University of Texas MD Anderson Cancer Center in the United States. Before joining the Banaras Hindu University, Dr. Gupta was an instructor at the University of Mississippi Medical Center in the United States. His current research is focused on uncovering the mechanism by which acidic microenvironment promote cancer growth. He is also working on cancer chemoprevention and on projects to elucidate the role of inflammatory pathways, cancer stem cells, exosomal microRNAs, and long noncoding RNAs in regulating tumor development. He has published over 100 peer-reviewed articles in highly prestigious journals. He has been honored with prestigious national and international awards. He has coedited special issues of scientific journals and three prestigious books. Currently he is an editorial board member on several scientific journals and an active reviewer on more than 80 journals.
Dr. Kishore B. Challagundla is an assistant professor in the Department of Biochemistry and Molecular Biology, the Children's Health Research Institute, and a member of the NCI-designated Fred & Pamela Buffet Cancer Center at the University of Nebraska Medical Center in Omaha, NE, United States. Dr. Challagundla earned a master's in Biochemistry from Bharathidasan University and a PhD in Biochemistry from the University of Lucknow, followed by postdoctoral training at the Mayo Clinic in Rochester, Minnesota Oregon Health & Science University in Portland, Oregon, and Children's Hospital Los Angeles in California. Challagundla 's lab research focuses on investigating the involvement of novel noncoding RNAs in therapy resistance, the role of exosomes in the cross-talk between tumor, microenvironment, and immune cells, the posttranslational modifications of immune checkpoint molecules by ubiquitination, and their potential role in escaping immune surveillance, the development of RNA-based diagnostic, prognostic, and therapy response predictive specific noninvasive biomarkers in body fluids, and the development of novel combination therapeutic strategies that maximize drug response without any toxicity in patients with high-risk neuroblastoma. Dr. Challagundla served as the principal investigator of several grants, including NIH, foundation, and institutional grants. Dr. Challagundla is an ad hoc reviewer to various national and international organizations such as NIH, Yorkshire Cancer Research (UK), University Grants Committee (Hong Kong), Dutch Cancer Society (The Netherlands), The Netherlands Organisation for Scientific Research (The Netherlands), Worldwide Cancer Research, The Indonesian Science Fund, The National Science Centre (Poland), The French National Cancer Institute (France), The Israel Science Foundation (Israel), Czech Science Foundation (Czech Republic), and The Natural Sciences and Engineering Research Council of Canada. Furthermore, Challagundla is an associate editor of various journals such as Molecular Therapy Nucleic Acids (Cell Press), Molecular Therapy Oncolytics (Cell press), PLoS One, BMC Molecular & Cellular Biology, Cancer Cell International, and an editorial board member of Cancers, The Journal of Extracellular Vesicles, and an active reviewer for more than 100 top international journals. Challagundla has published over 40 peer-reviewed articles in high-impact journals, written several book chapters, and is a recipient of various national and international awards.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

24.01.2022

Abbildungen

70 illustrations (40 in full color)

Herausgeber

Verlag

Elsevier Science & Technology

Seitenzahl

478

Maße (L/B/H)

23,4/19,1/1,8 cm

Gewicht

998 g

Sprache

Englisch

ISBN

978-0-12-824550-7

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: gpsr@libri.de

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
Die Leseprobe wird geladen.
  • Produktbild: Clinical Applications of Noncoding Rnas in Cancer

  • 1. Noncoding ribonucleic acid for pancreatic cancer therapy2. Applications of noncoding RNAs in brain cancer patients3. Noncoding RNAs in colorectal cancerpatients4. Applications of noncoding ribonucleic acids in multiple myeloma patients5. Clinical applications of noncoding RNAs in lung cancer patients6. Noncoding RNAs in intraocular tumor patients7. Applications of noncoding RNAs in renal cancer patients8. Clinical significance of long noncoding RNAs in breast cancer patients9. Noncoding ribonucleic acids in gastric cancer patients10. Noncoding RNAs in prostate cancer patients11. Noncoding RNAs in liver cancer patients12. Noncoding ribonucleic acids in gallbladder cancer patients13. Clinical implications of noncoding ribonucleic acids in neuroblastoma patients14. Potential clinical application of lncRNAs in pediatric cancer